Shionogi B.V.

The sponsor is involved in clinical studies for late-onset Pompe disease, a lysosomal storage disorder associated with progressive muscle and respiratory impairment. This area of interest centers on supportive approaches alongside enzyme replacement therapy, with emphasis on lung function and disease burden in affected adults.

• Late-onset Pompe disease
• Respiratory muscle involvement
• Enzyme replacement therapy

These studies place the sponsor within rare disease research that addresses chronic functional decline and multisystem involvement.

Shionogi B.V. Medical Sciences also funds research in respiratory syncytial virus infection, including symptomatic disease in adults at elevated risk of progression to severe illness. The therapeutic interest is centered on antiviral treatment for community-managed respiratory infection and the prevention of worsening respiratory outcomes.

• Respiratory syncytial virus
• Symptomatic outpatient infection
• High-risk adult respiratory disease

This area links the sponsor to clinical efforts in infectious disease and respiratory medicine.

The sponsor’s portfolio includes studies in acute ischemic stroke, focusing on treatment approaches for adults with recent cerebral ischemic injury. This therapeutic domain falls within neurology and emergency care, where rapid intervention is central to limiting neurological damage and improving recovery potential.

• Acute ischemic stroke
• Cerebrovascular injury
• Neurological recovery

Clinical research in this field reflects interest in acute stroke therapy and related vascular neurology care.